Danish biotech companies consider a move abroad
A survey shows that the passing of a new controversial tax law has a number of Danish biotech companies considering a partial or complete move abroad.
by Stefan Singh Kailay
“It goes without saying that when you have to pay taxes even though you have accumulated tax assets, it does not bode well,” President of the business association Danks Biotek, Martin Bonde, says following a survey among Danish biotech companies showing that 19 % of them consider a partial or complete move abroad due to the new L 173 tax rules.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
- Adgang til alle låste artikler
- Modtag vores daglige nyhedsbreve
- Fuld adgang til vores app
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler:
Bavarian-CEO: operational improvements will continue
For abonnenter
